Leerink Partners analyst Jonathan Chang maintained a Buy rating on Zai Lab (NASDAQ:ZLAB) on Wednesday, setting a price target of $200, which is approximately 66.86% above the present share price of $119.86.
Chang expects Zai Lab to post earnings per share (EPS) of -$1.76 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Zai Lab, with an average price target of $215.67.
The analysts price targets range from a high of $225 to a low of $200.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $36.94 million and a net profit of -$170.57 million. The company's market cap is $9.03 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 6.1% and a 34.38% success rate.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.